Vertex Pharmaceuticals Incorporated (VRTX) Net Profit Margin: 32.74%
Is Vertex Pharmaceuticals Incorporated’s net profit margin high or low?
Vertex Pharmaceuticals Incorporated's net profit margin of 32.74% is 11% above its 5-year average of 29.40%, near the high end of its 5-year range (-4.86%–43.70%).
The net profit margin for Vertex Pharmaceuticals Incorporated (VRTX) is 32.74% as of Tuesday, June 9, 2026. It is above its 12-month average by 134.86% (13.94%).
VRTX Net Profit Margin Chart
VRTX Average Net Profit Margin Chart
VRTX Current vs Average Net Profit Margin Chart
VRTX Net Profit Margin Metrics
NET PROFIT MARGIN
32.74%
NET PROFIT MARGIN AVG TTM
13.94%
NET PROFIT MARGIN AVG 3Y
25.44%
NET PROFIT MARGIN AVG 5Y
29.40%
NET PROFIT MARGIN AVG 10Y
20.31%
NET PROFIT MARGIN AVG 15Y
-29.49%
NET PROFIT MARGIN AVG 20Y
-84.82%
CURRENT VS TTM AVG
+134.86%
CURRENT VS 3Y AVG
+28.69%
CURRENT VS 5Y AVG
+11.37%
CURRENT VS 10Y AVG
+61.21%
CURRENT VS 15Y AVG
+211.02%
CURRENT VS 20Y AVG
+138.60%
VRTX Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 32.74% | 13.94% | 25.44% | 29.40% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 14.63% | -1.95% | 6.91% | 3.59% |
| Medtronic plc (MDT) | $105.25B | 13.20% | 13.55% | 12.62% | 13.06% |
| CVS Health Corporation (CVS) | $123.84B | 0.44% | 0.84% | 1.34% | 1.79% |
| Danaher Corporation (DHR) | $133.37B | 14.71% | 15.52% | 19.51% | 19.37% |
| Elevance Health Inc. (ELV) | $92.17B | 2.84% | 3.11% | 3.37% | 3.60% |
| Pfizer Inc. (PFE) | $146.48B | 12.42% | 12.51% | 14.97% | 18.18% |
| Cigna Corporation (CI) | $78.04B | 2.17% | 1.78% | 2.48% | 3.04% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 28.38% | 28.09% | 25.67% | 26.14% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 28.90% | 15.29% | 17.07% | 15.27% |
Margin Comparison
Operating Margin
39.4%
Net Profit Margin
32.7%
Vertex Pharmaceuticals Incorporated Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Net Profit Margin FAQ
- What is the net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The net profit margin for VRTX stock is 32.74%.
- Is Vertex Pharmaceuticals Incorporated's net profit margin high or low?
- Vertex Pharmaceuticals Incorporated's net profit margin of 32.74% is 11% above its 5-year average of 29.40%, near the high end of its 5-year range (-4.86%–43.70%).
- What is the TTM average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average net profit margin for VRTX stock is 13.94%.
- What is the 3Y average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average net profit margin for VRTX stock is 25.44%.
- What is the 5Y average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average net profit margin for VRTX stock is 29.40%.
- What is the 10Y average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average net profit margin for VRTX stock is 20.31%.
- What is the 15Y average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average net profit margin for VRTX stock is -29.49%.
- What is the 20Y average net profit margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average net profit margin for VRTX stock is -84.82%.
Vertex Pharmaceuticals Incorporated Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 32.74% |
| 2024-12-31 | -4.86% |
| 2023-12-31 | 36.68% |
| 2022-12-31 | 37.20% |
| 2021-12-31 | 30.92% |
| 2020-12-31 | 43.70% |
| 2019-12-31 | 28.27% |
| 2018-12-31 | 68.80% |
| 2017-12-31 | 10.59% |
| 2016-12-31 | -6.58% |
| 2015-12-31 | -54.06% |
| 2014-12-31 | -127.25% |
| 2013-12-31 | -36.72% |
| 2012-12-31 | -7.01% |
| 2011-12-31 | 2.10% |
| 2010-12-31 | -526.35% |
| 2009-12-31 | -628.70% |
| 2008-12-31 | -262.02% |
| 2007-12-31 | -196.61% |
| 2006-12-31 | -95.63% |
| 2005-12-31 | -126.43% |
| 2004-12-31 | -161.85% |
| 2003-12-31 | -284.59% |
| 2002-12-31 | -67.43% |
| 2001-12-31 | -39.54% |
| 2000-12-31 | -50.76% |
| 1999-12-31 | -66.56% |
| 1998-12-31 | -74.55% |
| 1997-12-31 | -45.21% |
| 1996-12-31 | -300.75% |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani